Shandong Weigao Group Medical Polymer Co. Ltd. Class H
0.38
EUR
+0.00
(-1.14%)
ISIN
CNE100000171
Return %
Stock
S&P 500
1Y
-37.14
14.20
3Y
-54.99
81.12
5Y
-74.29
68.34
Capital Structure
CNY
•
in mil. unless spec.Working Capital
CNY
•
in mil. unless spec.Growth Rates
CNY
•
in mil. unless spec.Semi-annual Revenue
CNY
•
in mil. unless spec.Semi-annual Earnings Per Share
CNY
•
in mil. unless spec.Semi-annual Dividends Per Share
CNY
•
in mil. unless spec.Company Description
- CEO
- Rinan Cong
- Full Time Employees
- 13,307
- Sector
- Health technology
- Industry
- Medical specialties
- Address
- 1 Weigao Road Weihai SD China 264210
- IPO Date
- Feb 27, 2004
- Website
- en.weigaogroup.com
- Similar Companies
- Business
- Shandong Weigao Group Medical Polymer Company Limited engages in the research and development, production, wholesale, and sale of medical devices primarily in China and internationally. The company offers a wide range of core products and services including single-use medical consumables such as infusion sets, syringes, medical needles, blood bags, pre-filled syringes, and blood sampling products; orthopedic materials and instruments including trauma products, spinal implants, artificial joints, PRP treatment consumables, and negative pressure drainage consumables; pharmaceutical packaging products such as prefilled drug delivery systems, pharmaceutical packaging consumables, automatic drug delivery systems, and pre-filled syringes; interventional products including tumor, vascular, and nursing interventions; and blood management products comprising whole blood collection consumables and blood transfusion equipment. Additionally, the company provides finance leasing and factoring services, medical PVC granules, plastic packing bags and carton boxes, medical polymer materials and products, injection puncture instruments, computer technical services, consulting services, and X-ray based irradiation machines. Founded in 1993 and headquartered in Shandong, China, Weigao Group is a leading comprehensive solution provider for the medical device industry. Recent major company developments include its continued expansion and strengthening of international collaboration, notably with Medtronic, which holds a 15% stake, to boost its presence in China's middle to low-end medical device market and internationally. In 2025, the company initiated an equity buyback plan and formed a joint venture to expand its market in Indonesia, demonstrating strategic moves to enhance market penetration and operational scale abroad. It also launched new products such as non-phthalic light-avoiding automatic stop infusion devices and has sustained product certification and quality standards, including CE certification for many of its infusion sets, syringes, and blood transfusion products. The company has also pursued acquisitions, notably the 2017 acquisition of U.S.-based Argon Medical Devices Holdings Inc. for $850 million to bolster its portfolio and market reach. These efforts align with its strategy to maintain leadership in single-use consumables and grow export opportunities for its own branded products in the global medical device market.
Company News
Shandong Weigao Medical Polymer Co. (OTCMKTS:SHWGF) Short Interest Up 97.6% in March
Shandong Weigao Medical Polymer (SHWGF) to Release Earnings on Friday
Shandong Weigao Medical Polymer (OTCMKTS:SHWGF) & AdaptHealth (NASDAQ:AHCO) Financial Analysis